Login to Your Account

Move Provides Resources for Cabo Development

Exelixis Hands Merck PI3K-Delta Program in $251M Deal

By Marie Powers
Staff Writer

Thursday, December 22, 2011

True to its word, Exelixis Inc. started to prune its pipeline this week, handing Merck & Co. Inc. an exclusive worldwide license to its phosphoinositide-3 kinase (PI3K)-delta research and development program, including XL499 – the company's most advanced preclinical PI3K-delta inhibitor – and related compounds.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription